Nifty

:

25790.25

Sensex

:

83878.17

106.95 (0.42%)
301.93 (0.36%)

Login

Nifty
Sensex

:
:

25790.25
83878.17

106.95 (0.42%)
301.93 (0.36%)

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

Rating :

55/99

BSE: 543635 | NSE: PPLPHARMA

Watchlist

NSE BSE

168.53

09-Jan-2026

Open
High
Low
Previous Close

172.8
173.71
167.81
172.71

Volume
Traded Value (lacs)
52 Week High
52 Week Low

2463860
418843668.46
251.95
165.12

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

22,411.12
N/A
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

26,604.98
0.08%
2.77

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
7.70
8.92

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-0.14
17.68

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-35.79
115.07

P:E (Median)

8 Years
5 Years
3 Years

-
-
-

P:BV (Average)

8 Years
5 Years
3 Years

-
-
2.73

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
19.33

Earnings Forecasts:

(Updated: 10-01-2026)

Description 2024 2025 2026 2027
Adj EPS 0.69 0.6 3.71 6.07
P/E Ratio 244.25 280.88 45.43 27.76
Revenue 9061 9306.48 10909.9 12391.5
EBITDA 1444.83 1093.82 1773.88 2226.23
Net Income 91.13 76.92 491.12 803.88
ROA 0.59 0.31 2.91 4.8
P/B Ratio 1.10 1.05 0.95 0.87
ROE 1.14 1.49 5.97 8.73
FCFF
FCFF Yield
Net Debt 2318.4 -1220.7 -221.1 -86.05
BVPS 152.73 160.54 176.53 193.68

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var%
Net Sales 1,127.26 1,284.39 -12.23% 969.88 1,063.20 -8.78% 1,689.80 1,525.30 10.78% 1,248.32 1,024.14 21.89%
Expenses 1,000.19 1,031.50 -3.04% 925.55 911.57 1.53% 1,273.22 1,135.66 12.11% 1,028.98 898.61 14.51%
EBITDA 127.07 252.89 -49.75% 44.33 151.63 -70.76% 416.58 389.64 6.91% 219.34 125.53 74.73%
EBIDTM 11.27% 19.69% 4.57% 14.26% 24.65% 25.55% 17.57% 12.26%
Other Income 201.97 106.38 89.86% 180.92 36.76 392.17% 39.51 53.19 -25.72% 24.70 33.11 -25.40%
Interest 20.38 29.95 -31.95% 23.23 24.88 -6.63% 30.56 27.66 10.48% 29.17 17.42 67.45%
Depreciation 61.25 53.61 14.25% 59.44 51.85 14.64% 61.17 52.50 16.51% 55.46 51.56 7.56%
PBT 247.41 275.71 -10.26% 142.58 111.66 27.69% 364.36 362.67 0.47% 159.41 89.66 77.79%
Tax 51.08 65.65 -22.19% 29.44 26.39 11.56% 87.09 89.59 -2.79% 40.61 15.32 165.08%
PAT 196.33 210.06 -6.54% 113.14 85.27 32.68% 277.27 273.08 1.53% 118.80 74.34 59.81%
PATM 17.42% 16.35% 11.67% 8.02% 16.41% 17.90% 9.52% 7.26%
EPS 1.48 1.58 -6.33% 0.85 0.64 32.81% 2.09 2.05 1.95% 0.89 0.56 58.93%

Description Sep 25 Sep 24 Var% Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var%
Net Sales 2,043.72 2,241.75 -8.83% 1,933.71 1,951.14 -0.89% 2,754.07 2,552.36 7.90% 2,204.22 1,958.57 12.54%
Expenses 1,885.03 1,900.14 -0.80% 1,827.01 1,746.65 4.60% 2,193.08 2,022.43 8.44% 1,866.48 1,690.20 10.43%
EBITDA 158.69 341.61 -53.55% 106.70 204.49 -47.82% 560.99 529.93 5.86% 337.74 268.37 25.85%
EBIDTM 7.76% 15.24% 5.52% 10.48% 20.37% 20.76% 15.32% 13.70%
Other Income 65.60 61.11 7.35% 58.40 19.54 198.87% 42.03 26.38 59.33% 12.13 61.51 -80.28%
Interest 82.42 107.64 -23.43% 86.15 106.96 -19.46% 103.68 114.22 -9.23% 103.31 105.88 -2.43%
Depreciation 202.84 192.22 5.52% 197.28 184.55 6.90% 242.76 196.13 23.78% 196.81 186.32 5.63%
PBT -60.97 102.86 - -97.59 -67.48 - 256.58 215.44 19.10% 49.75 5.41 819.59%
Tax 53.04 97.53 -45.62% 2.68 43.56 -93.85% 119.30 126.21 -5.48% 63.12 9.25 582.38%
PAT -114.01 5.33 - -100.27 -111.04 - 137.28 89.23 53.85% -13.37 -3.84 -
PATM -5.58% 0.24% -5.19% -5.69% 4.98% 3.50% -0.61% -0.20%
EPS -0.75 0.17 - -0.62 -0.67 - 1.16 0.77 50.65% 0.03 0.08 -62.50%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 5,035.26 5,285.71 4,390.11 3,443.22 3,340.42 2,938.81 Net Sales Growth 2.82% 20.40% 27.50% 3.08% 13.67% Cost Of Goods Sold 2,137.28 2,245.96 2,108.84 1,768.48 1,561.51 1,227.77 Gross Profit 2,897.98 3,039.75 2,281.27 1,674.74 1,778.91 1,711.04 GP Margin 57.55% 57.51% 51.96% 48.64% 53.25% 58.22% Total Expenditure 4,227.94 4,276.55 3,790.71 3,345.69 2,865.14 2,319.88 Power & Fuel Cost - 131.62 112.89 107.94 83.83 68.08 % Of Sales - 2.49% 2.57% 3.13% 2.51% 2.32% Employee Cost - 736.19 613.93 548.50 448.03 395.15 % Of Sales - 13.93% 13.98% 15.93% 13.41% 13.45% Manufacturing Exp. - 356.88 317.98 318.40 283.52 246.85 % Of Sales - 6.75% 7.24% 9.25% 8.49% 8.40% General & Admin Exp. - 420.18 341.84 310.59 261.25 209.20 % Of Sales - 7.95% 7.79% 9.02% 7.82% 7.12% Selling & Distn. Exp. - 253.98 212.89 230.60 182.88 135.62 % Of Sales - 4.81% 4.85% 6.70% 5.47% 4.61% Miscellaneous Exp. - 131.74 82.34 61.18 44.12 37.21 % Of Sales - 2.49% 1.88% 1.78% 1.32% 1.27% EBITDA 807.32 1,009.16 599.40 97.53 475.28 618.93 EBITDA Margin 16.03% 19.09% 13.65% 2.83% 14.23% 21.06% Other Income 447.10 238.63 220.58 341.07 224.79 197.97 Interest 103.34 114.56 107.10 115.87 57.29 4.71 Depreciation 237.32 222.09 205.26 192.08 165.37 143.64 PBT 913.76 911.14 507.62 130.65 477.41 668.55 Tax 208.22 219.74 116.40 54.19 94.79 115.28 Tax Rate 22.79% 24.12% 22.93% 43.81% 20.50% 16.79% PAT 705.54 691.40 391.22 69.50 367.54 571.50 PAT before Minority Interest 705.54 691.40 391.22 69.50 367.54 571.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 14.01% 13.08% 8.91% 2.02% 11.00% 19.45% PAT Growth 9.77% 76.73% 462.91% -81.09% -35.69% EPS 5.31 5.20 2.94 0.52 2.77 4.30

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 8,935.72 9,151.18 8,171.16 7,081.55 6,559.10 6,314.90 Net Sales Growth 2.66% 11.99% 15.39% 7.97% 3.87% Cost Of Goods Sold 3,157.36 3,231.65 2,954.00 2,703.30 2,451.26 2,059.11 Gross Profit 5,778.36 5,919.53 5,217.16 4,378.25 4,107.84 4,255.79 GP Margin 64.67% 64.69% 63.85% 61.83% 62.63% 67.39% Total Expenditure 7,771.60 7,733.31 7,000.65 6,453.31 5,609.44 4,886.94 Power & Fuel Cost - 267.16 241.59 207.81 163.56 136.70 % Of Sales - 2.92% 2.96% 2.93% 2.49% 2.16% Employee Cost - 2,307.47 2,029.50 1,896.35 1,588.83 1,467.74 % Of Sales - 25.21% 24.84% 26.78% 24.22% 23.24% Manufacturing Exp. - 774.18 731.64 674.10 589.03 544.09 % Of Sales - 8.46% 8.95% 9.52% 8.98% 8.62% General & Admin Exp. - 563.04 542.00 472.78 428.49 367.25 % Of Sales - 6.15% 6.63% 6.68% 6.53% 5.82% Selling & Distn. Exp. - 398.11 359.75 372.59 317.81 247.91 % Of Sales - 4.35% 4.40% 5.26% 4.85% 3.93% Miscellaneous Exp. - 191.70 142.17 126.38 70.46 64.14 % Of Sales - 2.09% 1.74% 1.78% 1.07% 1.02% EBITDA 1,164.12 1,417.87 1,170.51 628.24 949.66 1,427.96 EBITDA Margin 13.03% 15.49% 14.32% 8.87% 14.48% 22.61% Other Income 178.16 161.77 201.14 225.11 275.80 164.11 Interest 375.56 421.59 448.49 344.18 198.25 163.45 Depreciation 839.69 816.34 740.57 676.69 586.18 545.04 PBT 147.77 341.71 182.59 -167.52 441.03 883.58 Tax 238.14 323.51 161.47 66.31 109.02 114.02 Tax Rate 161.16% 94.67% 134.78% -38.00% 25.59% 12.64% PAT -90.37 91.13 17.82 -186.46 375.96 835.03 PAT before Minority Interest -90.37 91.13 17.82 -186.46 375.96 835.03 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin -1.01% 1.00% 0.22% -2.63% 5.73% 13.22% PAT Growth 0.00% 411.39% - - -54.98% EPS -0.68 0.69 0.13 -1.40 2.83 6.28

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 7,452.54 6,712.07 5,261.79 5,123.12 4,100.62 Share Capital 1,324.35 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,064.63 5,361.65 4,068.47 3,937.21 3,105.92 Non-Current Liabilities 1,199.34 859.80 1,083.17 800.72 184.38 Secured Loans 356.84 363.94 592.34 477.12 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 615.10 281.04 274.43 143.85 6.59 Current Liabilities 2,306.49 2,307.35 1,951.29 1,655.39 1,566.96 Trade Payables 1,184.76 1,107.71 761.67 646.80 584.12 Other Current Liabilities 426.66 503.64 430.07 488.22 681.78 Short Term Borrowings 652.22 531.64 720.34 390.21 165.20 Short Term Provisions 42.85 164.36 39.21 130.16 135.86 Total Liabilities 10,958.37 9,879.22 8,296.25 7,579.23 5,851.96 Net Block 2,894.28 2,612.16 2,601.87 2,438.98 1,626.81 Gross Block 4,258.04 3,766.97 3,564.57 3,225.28 2,260.11 Accumulated Depreciation 1,363.76 1,154.81 962.70 786.30 633.30 Non Current Assets 7,422.49 6,508.14 5,947.57 5,400.24 3,989.17 Capital Work in Progress 327.30 533.24 416.57 405.16 121.00 Non Current Investment 3,105.31 1,646.88 1,646.87 1,592.52 1,591.52 Long Term Loans & Adv. 1,095.60 1,715.86 1,282.22 963.54 649.84 Other Non Current Assets 0.00 0.00 0.04 0.04 0.00 Current Assets 3,535.88 3,371.08 2,348.68 2,178.99 1,862.79 Current Investments 0.00 61.28 100.12 37.01 0.00 Inventories 1,205.35 1,153.04 818.61 535.51 420.88 Sundry Debtors 1,666.69 1,331.38 909.56 989.22 839.75 Cash & Bank 177.84 241.73 64.16 137.23 152.35 Other Current Assets 486.00 60.24 28.98 39.00 449.81 Short Term Loans & Adv. 369.13 523.41 427.25 441.02 405.31 Net Current Assets 1,229.39 1,063.73 397.39 523.60 295.83 Total Assets 10,958.37 9,879.22 8,296.25 7,579.23 5,851.96

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 8,125.47 7,911.37 6,773.50 6,696.60 5,605.00 Share Capital 1,324.35 1,322.95 1,193.32 1,185.91 994.60 Total Reserves 6,738.96 6,560.95 5,580.18 5,510.69 4,610.30 Non-Current Liabilities 3,392.72 2,644.64 3,812.00 2,902.58 2,560.38 Secured Loans 3,214.07 2,483.75 3,383.54 2,622.14 2,339.16 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 48.66 32.32 275.97 145.34 6.78 Current Liabilities 3,766.27 4,369.30 3,851.04 3,118.01 2,590.70 Trade Payables 1,533.77 1,538.37 1,192.71 1,026.35 917.94 Other Current Liabilities 1,184.72 1,575.68 1,305.30 1,242.76 1,140.63 Short Term Borrowings 995.32 1,171.38 1,302.29 658.76 360.52 Short Term Provisions 52.46 83.87 50.74 190.14 171.61 Total Liabilities 15,284.46 14,925.31 14,436.54 12,717.19 10,756.08 Net Block 8,133.43 7,989.93 7,468.60 6,879.18 6,105.49 Gross Block 13,117.63 12,137.48 10,842.12 9,510.49 8,173.25 Accumulated Depreciation 4,984.20 4,147.55 3,373.52 2,631.31 2,067.76 Non Current Assets 9,487.47 9,460.84 9,593.07 8,565.30 7,006.96 Capital Work in Progress 976.90 1,115.80 1,418.58 1,172.34 626.65 Non Current Investment 271.09 240.26 211.87 216.77 122.67 Long Term Loans & Adv. 91.08 114.85 493.98 296.97 152.11 Other Non Current Assets 14.97 0.00 0.04 0.04 0.04 Current Assets 5,796.99 5,464.47 4,843.47 4,151.89 3,749.12 Current Investments 19.56 144.69 427.11 50.40 0.00 Inventories 2,312.70 2,175.88 1,681.37 1,388.80 1,232.00 Sundry Debtors 2,349.52 2,134.43 1,799.34 1,785.28 1,574.94 Cash & Bank 501.46 482.56 307.56 328.99 405.62 Other Current Assets 613.75 81.93 140.24 93.66 536.56 Short Term Loans & Adv. 478.88 444.98 487.85 504.76 395.55 Net Current Assets 2,030.72 1,095.17 992.43 1,033.88 1,158.42 Total Assets 15,284.46 14,925.31 14,436.54 12,717.19 10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 548.77 358.29 71.52 249.19 34.72 PBT 911.14 507.62 123.69 477.41 349.11 Adjustment 264.51 221.26 50.70 42.92 8.96 Changes in Working Capital -392.59 -292.78 -42.84 -168.48 -228.06 Cash after chg. in Working capital 783.06 436.10 131.55 351.85 130.01 Interest Paid 0.00 0.00 0.00 0.00 0.00 Tax Paid -234.29 -77.81 -60.03 -102.66 -95.29 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -549.98 -635.52 -435.05 -1,245.61 -4,382.89 Net Fixed Assets -285.13 -319.07 -350.70 -1,249.33 Net Investments -1,397.15 38.83 -117.46 -38.01 Others 1,132.30 -355.28 33.11 41.73 Cash from Financing Activity -61.74 451.38 290.12 896.40 4,494.16 Net Cash Inflow / Outflow -62.95 174.15 -73.41 -100.02 145.99 Opening Cash & Equivalents 228.80 54.28 127.69 146.72 0.74 Closing Cash & Equivalent 163.87 228.80 54.28 127.69 146.73

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 892.30 1,004.54 483.89 766.42 597.58 PBT 341.71 119.80 -160.56 441.03 639.68 Adjustment 1,372.66 1,275.88 1,135.53 787.10 721.99 Changes in Working Capital -487.72 -234.30 -302.08 -292.29 -619.58 Cash after chg. in Working capital 1,226.65 1,161.38 672.89 935.84 742.09 Interest Paid 0.00 0.00 0.00 0.00 0.00 Tax Paid -334.35 -156.84 -189.00 -169.42 -144.51 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -477.46 -434.01 -1,338.78 -1,812.10 -4,479.93 Net Fixed Assets -285.13 -319.07 -350.70 -1,249.33 Net Investments -1,397.15 38.83 -117.46 -38.01 Others 1,204.82 -153.77 -870.62 -524.76 Cash from Financing Activity -440.83 -422.36 817.79 794.19 3,976.83 Net Cash Inflow / Outflow -25.99 148.17 -37.10 -251.49 94.48 Opening Cash & Equivalents 219.19 53.23 85.18 261.97 151.95 Closing Cash & Equivalent 182.32 219.19 53.23 85.18 261.97

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 55.79 50.53 43.06 42.19 41.23 ROA 6.64% 4.30% 0.88% 5.47% 9.77% ROE 9.83% 6.55% 1.34% 7.97% 13.94% ROCE 12.40% 8.33% 3.64% 9.86% 16.21% Fixed Asset Turnover 1.36 1.26 1.05 1.24 1.30 Receivable days 100.49 88.86 96.97 98.40 104.30 Inventory Days 79.05 78.18 69.15 51.45 52.27 Payable days 186.28 161.78 145.35 143.86 173.65 Cash Conversion Cycle -6.74 5.26 20.77 5.99 -17.08 Total Debt/Equity 0.17 0.17 0.31 0.23 0.04 Interest Cover 8.95 5.74 2.07 9.07 146.81

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 60.88 59.59 55.44 55.15 56.35 ROA 0.60% 0.12% -1.37% 3.20% 7.76% ROE 1.14% 0.24% -2.77% 6.11% 14.90% ROCE 6.61% 5.07% 1.95% 7.10% 13.06% Fixed Asset Turnover 0.84 0.82 0.80 0.83 0.77 Receivable days 77.05 76.20 80.70 83.94 91.03 Inventory Days 77.13 74.72 69.11 65.47 71.21 Payable days 173.49 168.73 149.81 144.76 162.72 Cash Conversion Cycle -19.30 -17.80 0.00 4.65 -0.47 Total Debt/Equity 0.59 0.58 0.81 0.60 0.52 Interest Cover 1.98 1.40 0.65 3.45 6.81

Top Investors:

ca alchemy investments

hdfc trustee company limited-hdfc flexi cap fund

east bridge capital master fund i ltd

indiahold limited

canara robeco mutual fund a/c canara robeco small cap fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

USFDA concludes GMP inspection at Piramal Pharma’s USA facility
12th Dec 2025, 10:13 AM

At the conclusion of the inspection, the USFDA issued a Form-483, with four observations
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback